276237-03-7

Basic information

• Product Name: 4-(5-PIPERIDIN-4-YL-1,2,4-OXADIAZOL-3-YL)PYRIDINE
• Synonyms: 4-[3-(Pyridin-4-yl)-1,2,4-oxadiazol-5-yl]piperidine, 5-(Piperidin-4-yl)-3-(pyridin-4-yl)-1,2,4-oxadiazole
• CAS NO: 276237-03-7
• Molecular Formula: C₁₂H₁₄N₄O
• Molecular Weight: 230.27
• Mol File: 276237-03-7.mol
• Article Data: 2

Chemical Properties

• Melting Point: 82～85℃
• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4-(5-PIPERIDIN-4-YL-1,2,4-OXADIAZOL-3-YL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-PIPERIDIN-4-YL-1,2,4-OXADIAZOL-3-YL)PYRIDINE(276237-03-7)
• EPA Substance Registry System: 4-(5-PIPERIDIN-4-YL-1,2,4-OXADIAZOL-3-YL)PYRIDINE(276237-03-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 276237-03-7(Hazardous Substances Data)

Usage

General Description

4-(5-Piperidin-4-yl-1,2,4-oxidiazol-3-yl)pyridine is a chemical compound that contains both a pyridine and an oxadiazole ring. Pyridine is a basic heterocyclic organic compound similar to benzene, and widely used as an important raw material and solvent in the production of pesticides, drugs, and dyes. Oxadiazole is a heterocyclic compound containing an atom of oxygen and two nitrogen atoms. This chemical is from the family of Piperidines and may be used in pharmaceutical research, but there is no detailed information available about its specific applications, properties, or potential health effects. The compound, however, points to a complex structure that suggests the synthesis would be required for a specific function or role in a particular research or industrial context.

Upstream product

• 74901-69-2 2,4-dichloro-6,7-dihydro-thieno[3,2-d]pyrimidine 
• 1143575-83-0 (R)-2-(2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-ylamino)-3-methyl-butan-1-ol 
• 1143575-82-9 (R)-2-(2-chloro-6,7-dihydro-thieno[3,2-d]pyrimidin-4-ylamino)-3-methyl-butan-1-ol 

Relevant articles and documents

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.